Trial Profile
RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancers With Focus on Urothelial Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Sarcoma; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Acronyms RESOLVE
- 10 Oct 2023 Status changed from suspended to recruiting.
- 02 Aug 2023 Planned End Date changed from 30 Nov 2025 to 30 Nov 2026.
- 02 Aug 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Nov 2024.